Literature DB >> 15499633

Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.

Kunle Odunsi1, Robert M Wollman, Christine B Ambrosone, Alan Hutson, Susan E McCann, Jonathan Tammela, John P Geisler, Gregory Miller, Thomas Sellers, William Cliby, Feng Qian, Bernadette Keitz, Marilyn Intengan, Shashikant Lele, James L Alderfer.   

Abstract

Currently available serum biomarkers are insufficiently reliable to distinguish patients with epithelial ovarian cancer (EOC) from healthy individuals. Metabonomics, the study of metabolic processes in biologic systems, is based on the use of (1)H-NMR spectroscopy and multivariate statistics for biochemical data generation and interpretation and may provide a characteristic fingerprint in disease. In an effort to examine the utility of the metabonomic approach for discriminating sera from women with EOC from healthy controls, we performed (1)H-NMR spectroscopic analysis on preoperative serum specimens obtained from 38 patients with EOC, 12 patients with benign ovarian cysts and 53 healthy women. After data reduction, we applied both unsupervised Principal Component Analysis (PCA) and supervised Soft Independent Modeling of Class Analogy (SIMCA) for pattern recognition. The sensitivity and specificity tradeoffs were summarized for each variable using the area under the receiver-operating characteristic (ROC) curve. In addition, we analyzed the regions of NMR spectra that most strongly influence separation of sera of EOC patients from healthy controls. PCA analysis allowed correct separation of all serum specimens from 38 patients with EOC (100%) from all of the 21 premenopausal normal samples (100%) and from all the sera from patients with benign ovarian disease (100%). In addition, it was possible to correctly separate 37 of 38 (97.4%) cancer specimens from 31 of 32 (97%) postmenopausal control sera. SIMCA analysis using the Cooman's plot demonstrated that sera classes from patients with EOC, benign ovarian cysts and the postmenopausal healthy controls did not share multivariate space, providing validation for the class separation. ROC analysis indicated that the sera from patients with and without disease could be identified with 100% sensitivity and specificity at the (1)H-NMR regions 2.77 parts per million (ppm) and 2.04 ppm from the origin (AUC of ROC curve = 1.0). In addition, the regression coefficients most influential for the EOC samples compared to postmenopausal controls lie around delta3.7 ppm (due mainly to sugar hydrogens). Other loadings most influential for the EOC samples lie around delta2.25 ppm and delta1.18 ppm. These findings indicate that (1)H-NMR metabonomic analysis of serum achieves complete separation of EOC patients from healthy controls. The metabonomic approach deserves further evaluation as a potential novel strategy for the early detection of epithelial ovarian cancer. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15499633     DOI: 10.1002/ijc.20651

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  82 in total

1.  Revealing the metabonomic variation of EC using ¹H-NMR spectroscopy and its association with the clinicopathological characteristics.

Authors:  Ayshamgul Hasim; Hong Ma; Batur Mamtimin; Abulizi Abudula; Madiniyet Niyaz; Li-Wei Zhang; Juret Anwer; Ilyar Sheyhidin
Journal:  Mol Biol Rep       Date:  2012-06-27       Impact factor: 2.316

Review 2.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

3.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.

Authors:  Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela
Journal:  MAGMA       Date:  2006-12-15       Impact factor: 2.310

Review 4.  Metabonomics techniques and applications to pharmaceutical research & development.

Authors:  John C Lindon; Elaine Holmes; Jeremy K Nicholson
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

5.  Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases.

Authors:  Jason B Nikas; C Dirk Keene; Walter C Low
Journal:  J Comp Neurol       Date:  2010-10-15       Impact factor: 3.215

Review 6.  Metabolomics: moving to the clinic.

Authors:  Anders Nordström; Rolf Lewensohn
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-28       Impact factor: 4.147

Review 7.  Postgenomics diagnostics: metabolomics approaches to human blood profiling.

Authors:  Oxana Trifonova; Petr Lokhov; Alexander Archakov
Journal:  OMICS       Date:  2013-09-17

Review 8.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Interdependence of signal processing and analysis of urine 1H NMR spectra for metabolic profiling.

Authors:  Shucha Zhang; Cheng Zheng; Ian R Lanza; K Sreekumaran Nair; Daniel Raftery; Olga Vitek
Journal:  Anal Chem       Date:  2009-08-01       Impact factor: 6.986

10.  1H NMR metabolomics study of age profiling in children.

Authors:  Haiwei Gu; Zhengzheng Pan; Bowei Xi; Bryan E Hainline; Narasimhamurthy Shanaiah; Vincent Asiago; G A Nagana Gowda; Daniel Raftery
Journal:  NMR Biomed       Date:  2009-10       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.